A Phase 2 interventional study of Avatrombopag and Avatrombopag in Thrombocytopenia Related to Chronic Liver Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.
Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 10 in phase 2, and was the 1st registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–65
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 6 · Phase 4 4
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 50 across the 23 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 6 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing avatrombopag in Thrombocytopenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinetics (PK) of E5501.
Key Inclusion Criteria:
Chronic liver diseases due to one of the following three etiologies:
Chronic Viral Hepatitis from one of the following categories
NASH diagnosed as:
Alcoholic liver disease diagnosed as:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Avatrombopag
Drug: Avatrombopag · Drug: Placebo
Drug: Placebo
Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
Placebo or inactive substance once a day for up to 7 days
Percentage of Participants Experiencing Response
Platelet counts (PC) were determined from blood draws. A responder is defined as a participant having an increase of at least 20,000/mm\^3 PC from Baseline and a PC greater than 50,000/mm\^3 at least once during Day 4 through Day 8. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (end of treatment (EOT)), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
Time frame: Day 8 (Visit 5, EOT)
Change in Platelet Count on Day 8 (Visit 5 and/or End of Treatment) From Baseline
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
Time frame: Day 8 (Visit 5, EOT)
Percentage of Participants Experiencing Dose-response by Visit
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
Time frame: Day 4 (Visit 3), Day 6 ( Visit 4), Day 8 (Visit 5, EOT), 3 Day Post Last Dose (Visit 6), and 7 Day Post Last Dose (Visit 7)
Percentage of Participants Who Achieved a Platelet Count Greater Than 75,000/mm^3 on Day 4
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
Time frame: Day 4 (Visit 3)
Percentage of Participants Who Achieved a Platelet Count Greater Than 100,000/mm^3 on Days 4 and 8
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
Time frame: Day 4 (Visit 3) and Day 8 (Visit 5, EOT)
| Milestone | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 0 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| Started | 18 | 16 | 17 | 16 | 21 | 21 | 21 |
| Completed | 16 | 14 | 17 | 14 | 19 | 21 | 21 |
| Not completed | 2 | 2 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Administrative/other | 2 | 1 | 0 | 0 | 1 | 0 | 0 |
Platelet counts (PC) were determined from blood draws. A responder is defined as a participant having an increase of at least 20,000/mm\^3 PC from Baseline and a PC greater than 50,000/mm\^3 at least once during Day 4 through Day 8. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (end of treatment (EOT)), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
| Percentage of participants | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag , 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B:10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| Yes response | 38.9 | 31.3 | 76.5 | 6.3 | 42.9 | 52.4 | 9.5 |
| No response | 61.1 | 68.8 | 23.5 | 93.8 | 57.1 | 47.6 | 90.5 |
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
| K/mm^3 | Cohort A: 20 mg Aavatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Aavatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| Change in Platelet Count on Day 8 (Visit 5 and/or End of Treatment) From Baseline | 16.2 ± 10.32 | 15.9 ± 13.45 | 32.2 ± 18.59 | 3.1 ± 17.97 | 18.9 ± 10.07 | 24.9 ± 17.91 | 3.9 ± 12.49 |
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
| Percentage of participants | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A:40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| Yes response (Day 4, Visit 3) | 0 | 0 | 5.9 | 0 | 0 | 4.8 | 4.8 |
| No response (Day 4, Visit 3) | 100.0 | 100.0 | 94.1 | 100.0 | 100.0 | 95.2 | 95.2 |
| Yes response (Day 6, Visit 4) | 11.1 | 12.5 | 29.4 | 0 | 14.3 | 33.3 | 9.5 |
| No response (Day 6, Visit 4) | 88.9 | 87.5 | 70.6 | 100.0 | 85.7 | 66.7 | 90.5 |
| Yes response (Day 8, Visit 5) | 38.9 | 31.3 | 76.5 | 6.3 | 42.9 | 52.4 | 9.5 |
| No response (Day 8, Visit 5) | 61.1 | 68.8 | 23.5 | 93.8 | 57.1 | 47.6 | 90.5 |
| Yes response (3 Day post last dose, Visit 6) | 55.6 | 56.3 | 82.4 | 12.5 | 66.7 | 61.9 | 9.5 |
| No response (3 Day post last dose, Visit 6) | 44.4 | 43.8 | 17.6 | 87.5 | 33.3 | 38.1 | 90.5 |
| Yes response (7 Day post last dose, Visit 7) | 61.1 | 62.5 | 88.2 | 12.5 | 71.4 | 61.9 | 9.5 |
| No response (7 Day post last dose, Visit 7) | 38.9 | 37.5 | 11.8 | 87.5 | 28.6 | 38.1 | 90.5 |
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
| Percentage of participants | Cohort A: 20 mg Avatrombopag, IG Formulation | Cohort A: 40 mg Avatrombopag, IG Formulation | Cohort A: 80 mg Avatrombopag, IG Formulation | Cohort A: Placebo, IG Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| Yes response | 5.6 | 0 | 0 | 0 | 0 | 0 | 0 |
| No response | 94.4 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
| Percentage of participants | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| Yes response (Day 4, Visit 3) | 5.6 | 0 | 0 | 0 | 0 | 0 | 0 |
| No response (Day 4, Visit 3) | 94.4 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Yes response (Day 8, Visit 5) | 5.6 | 0 | 11.8 | 0 | 4.8 | 9.5 | 0 |
| No response (Day 8, Visit 5) | 94.4 | 100.0 | 88.2 | 100.0 | 95.2 | 90.5 | 100.0 |
Collected over Approximately 44 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: 20 mg Avatrombopag, 1G Formulation | 0/18 (0%) | 3/18 (16.7%) | 17/18 (94.4%) |
| Cohort A: 40 mg Avatrombopag, 1G Formulation | 0/16 (0%) | 2/16 (12.5%) | 13/16 (81.3%) |
| Cohort A: 80 mg Avatrombopag, 1G Formulation | 0/17 (0%) | 3/17 (17.6%) | 13/17 (76.5%) |
| Cohort A: Placebo, 1G Formulation | 0/16 (0%) | 1/16 (6.3%) | 12/16 (75%) |
| Cohort B: 10 mg Avatrombopag, 2G Formulation | 1/21 (4.8%) | 5/21 (23.8%) | 17/21 (81%) |
| Cohort B: 20 mg Avatrombopag, 2G Formulation | 0/21 (0%) | 3/21 (14.3%) | 18/21 (85.7%) |
| Cohort B: Placebo, 2G Formulation | 0/21 (0%) | 3/21 (14.3%) | 16/21 (76.2%) |
| Event | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/18 | 0/16 | 0/17 | 1/16 | 1/21 | 0/21 | 0/21 |
| SeromaInjury, poisoning and procedural complications | 0/18 | 1/16 | 0/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| Acute prerenal failureRenal and urinary disorders | 0/18 | 1/16 | 0/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| Gastric haemorrhageGastrointestinal disorders | 0/18 | 0/16 | 1/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| Liver disorderHepatobiliary disorders | 0/18 | 0/16 | 1/17 | 0/16 | 1/21 | 0/21 | 0/21 |
| Portal vein thrombosisHepatobiliary disorders | 0/18 | 0/16 | 1/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| AnaemiaBlood and lymphatic system disorders | 1/18 | 0/16 | 0/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/18 | 0/16 | 0/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| PneumoniaInfections and infestations | 1/18 | 0/16 | 0/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| Intentional overdoseInjury, poisoning and procedural complications | 1/18 | 0/16 | 0/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| Event | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/18 | 2/16 | 2/17 | 2/16 | 5/21 | 2/21 | 3/21 |
| Abdominal pain upperGastrointestinal disorders | 4/18 | 1/16 | 1/17 | 0/16 | 0/21 | 0/21 | 0/21 |
| Portal hypertensive gastropathyGastrointestinal disorders | 4/18 | 2/16 | 0/17 | 0/16 | 3/21 | 0/21 | 2/21 |
| FatigueGeneral disorders | 4/18 | 1/16 | 0/17 | 1/16 | 2/21 | 2/21 | 4/21 |
| VomitingGastrointestinal disorders | 1/18 | 2/16 | 3/17 | 0/16 | 0/21 | 1/21 | 1/21 |
| Abdominal painGastrointestinal disorders | 1/18 | 1/16 | 0/17 | 1/16 | 2/21 | 0/21 | 3/21 |
| AscitesGastrointestinal disorders | 1/18 | 1/16 | 1/17 | 0/16 | 0/21 | 1/21 | 3/21 |
| DiarrhoeaGastrointestinal disorders | 2/18 | 1/16 | 1/17 | 0/16 | 0/21 | 3/21 | 2/21 |
| PyrexiaGeneral disorders | 0/18 | 0/16 | 2/17 | 2/16 | 1/21 | 0/21 | 3/21 |
| DizzinessNervous system disorders | 2/18 | 0/16 | 1/17 | 1/16 | 3/21 | 1/21 | 1/21 |
Intent to Treat (ITT) population included all participants who were randomized into the study, received study medication, and had a post-treatment assessment.
| Age, Continuous(Years) | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 55.3 ± 7.16 | 52.8 ± 7.78 | 55.2 ± 5.96 | 54.2 ± 6.87 | 53.9 ± 5.48 | 56.8 ± 6.46 | 55.6 ± 6.52 | 54.8 ± 6.56 |
| Sex: Female, Male(Participants) | Cohort A: 20 mg Avatrombopag, 1G Formulation | Cohort A: 40 mg Avatrombopag, 1G Formulation | Cohort A: 80 mg Avatrombopag, 1G Formulation | Cohort A: Placebo, 1G Formulation | Cohort B: 10 mg Avatrombopag, 2G Formulation | Cohort B: 20 mg Avatrombopag, 2G Formulation | Cohort B: Placebo, 2G Formulation | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 6 | 5 | 10 | 7 | 7 | 42 |
| Male | 14 | 13 | 11 | 11 | 11 | 14 | 14 | 88 |
The record gives a start of May 2009, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 6 years 2 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag